Jay Olson
Stock Analyst at Oppenheimer
(4.05)
# 522
Out of 5,058 analysts
243
Total ratings
45.13%
Success rate
13.67%
Average return
Main Sectors:
Stocks Rated by Jay Olson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDGL Madrigal Pharmaceuticals | Maintains: Outperform | $600 → $650 | $552.10 | +17.73% | 12 | Nov 20, 2025 | |
| TERN Terns Pharmaceuticals | Maintains: Outperform | $20 → $17 | $26.48 | -35.80% | 3 | Oct 22, 2025 | |
| IBIO iBio, Inc. | Initiates: Outperform | $5 | $1.04 | +383.09% | 1 | Oct 21, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Outperform | $84 → $90 | $74.05 | +21.54% | 4 | Oct 8, 2025 | |
| IMRX Immuneering | Maintains: Outperform | $21 → $30 | $7.01 | +327.96% | 3 | Sep 25, 2025 | |
| BCYC Bicycle Therapeutics | Maintains: Outperform | $48 → $44 | $6.17 | +613.13% | 4 | Aug 11, 2025 | |
| MNMD Mind Medicine (MindMed) | Reinstates: Outperform | $25 | $11.20 | +123.21% | 1 | Aug 4, 2025 | |
| ATAI Atai Beckley | Initiates: Outperform | $14 | $3.75 | +273.33% | 1 | Jul 29, 2025 | |
| PRAX Praxis Precision Medicines | Maintains: Outperform | $97 → $115 | $172.00 | -33.14% | 2 | Jul 8, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Perform | $19 → $22 | $22.98 | -4.26% | 15 | Jun 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $10.04 | - | 15 | May 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $65 | $3.90 | +1,566.67% | 1 | May 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $65 | $1.82 | +3,471.43% | 5 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $13 | $1.78 | +630.34% | 3 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $75 | $70.54 | +6.32% | 9 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $90 | $57.02 | +57.84% | 6 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $42 | $16.97 | +147.50% | 4 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | $41 → $33 | $41.79 | -21.03% | 6 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $40 | $8.10 | +393.83% | 9 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $20 | $2.02 | +890.10% | 2 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $7.65 | +292.16% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $270 → $255 | $168.77 | +51.09% | 25 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $81 → $82 | $101.52 | -19.23% | 14 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $10 | $18.90 | -47.08% | 4 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $138 | $34.84 | +296.10% | 8 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $8 | $2.91 | +174.91% | 1 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $380 | $337.15 | +12.71% | 23 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $216 → $219 | $139.82 | +56.63% | 15 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $12 | $2.52 | +377.14% | 6 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 | $4.18 | +330.62% | 5 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 | $0.84 | +1,097.32% | 5 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $102 → $95 | $49.65 | +91.34% | 6 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $1.31 | +1,815.71% | 1 | Apr 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 | $1.33 | +579.25% | 4 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $1,200 → $500 | $1.36 | +36,664.71% | 4 | Nov 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $25 → $21 | $12.29 | +70.87% | 9 | Nov 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $4.32 | - | 2 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $84 | $17.40 | +382.76% | 1 | Mar 20, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $1.93 | - | 3 | Jul 11, 2017 |
Madrigal Pharmaceuticals
Nov 20, 2025
Maintains: Outperform
Price Target: $600 → $650
Current: $552.10
Upside: +17.73%
Terns Pharmaceuticals
Oct 22, 2025
Maintains: Outperform
Price Target: $20 → $17
Current: $26.48
Upside: -35.80%
iBio, Inc.
Oct 21, 2025
Initiates: Outperform
Price Target: $5
Current: $1.04
Upside: +383.09%
Ionis Pharmaceuticals
Oct 8, 2025
Maintains: Outperform
Price Target: $84 → $90
Current: $74.05
Upside: +21.54%
Immuneering
Sep 25, 2025
Maintains: Outperform
Price Target: $21 → $30
Current: $7.01
Upside: +327.96%
Bicycle Therapeutics
Aug 11, 2025
Maintains: Outperform
Price Target: $48 → $44
Current: $6.17
Upside: +613.13%
Mind Medicine (MindMed)
Aug 4, 2025
Reinstates: Outperform
Price Target: $25
Current: $11.20
Upside: +123.21%
Atai Beckley
Jul 29, 2025
Initiates: Outperform
Price Target: $14
Current: $3.75
Upside: +273.33%
Praxis Precision Medicines
Jul 8, 2025
Maintains: Outperform
Price Target: $97 → $115
Current: $172.00
Upside: -33.14%
ACADIA Pharmaceuticals
Jun 26, 2025
Maintains: Perform
Price Target: $19 → $22
Current: $22.98
Upside: -4.26%
May 27, 2025
Downgrades: Perform
Price Target: n/a
Current: $10.04
Upside: -
May 21, 2025
Initiates: Outperform
Price Target: $65
Current: $3.90
Upside: +1,566.67%
May 15, 2025
Maintains: Outperform
Price Target: $80 → $65
Current: $1.82
Upside: +3,471.43%
May 14, 2025
Maintains: Outperform
Price Target: $15 → $13
Current: $1.78
Upside: +630.34%
May 8, 2025
Maintains: Outperform
Price Target: $70 → $75
Current: $70.54
Upside: +6.32%
Mar 14, 2025
Upgrades: Outperform
Price Target: $90
Current: $57.02
Upside: +57.84%
Mar 3, 2025
Maintains: Outperform
Price Target: $50 → $42
Current: $16.97
Upside: +147.50%
Jan 24, 2025
Downgrades: Perform
Price Target: $41 → $33
Current: $41.79
Upside: -21.03%
Jan 13, 2025
Maintains: Outperform
Price Target: $60 → $40
Current: $8.10
Upside: +393.83%
Dec 11, 2024
Maintains: Outperform
Price Target: $80 → $20
Current: $2.02
Upside: +890.10%
Dec 6, 2024
Initiates: Outperform
Price Target: $30
Current: $7.65
Upside: +292.16%
Oct 31, 2024
Maintains: Outperform
Price Target: $270 → $255
Current: $168.77
Upside: +51.09%
Oct 30, 2024
Maintains: Outperform
Price Target: $81 → $82
Current: $101.52
Upside: -19.23%
Oct 17, 2024
Maintains: Outperform
Price Target: $9 → $10
Current: $18.90
Upside: -47.08%
Sep 25, 2024
Reiterates: Outperform
Price Target: $138
Current: $34.84
Upside: +296.10%
Aug 14, 2024
Assumes: Outperform
Price Target: $8
Current: $2.91
Upside: +174.91%
Aug 7, 2024
Maintains: Outperform
Price Target: $380
Current: $337.15
Upside: +12.71%
Aug 2, 2024
Maintains: Outperform
Price Target: $216 → $219
Current: $139.82
Upside: +56.63%
Jun 18, 2024
Maintains: Perform
Price Target: $12
Current: $2.52
Upside: +377.14%
May 15, 2024
Maintains: Outperform
Price Target: $18
Current: $4.18
Upside: +330.62%
May 15, 2024
Maintains: Outperform
Price Target: $10
Current: $0.84
Upside: +1,097.32%
May 10, 2024
Maintains: Outperform
Price Target: $102 → $95
Current: $49.65
Upside: +91.34%
Apr 12, 2024
Initiates: Outperform
Price Target: $25
Current: $1.31
Upside: +1,815.71%
Mar 27, 2024
Maintains: Outperform
Price Target: $9
Current: $1.33
Upside: +579.25%
Nov 30, 2023
Maintains: Outperform
Price Target: $1,200 → $500
Current: $1.36
Upside: +36,664.71%
Nov 22, 2023
Maintains: Perform
Price Target: $25 → $21
Current: $12.29
Upside: +70.87%
Oct 13, 2022
Downgrades: Perform
Price Target: n/a
Current: $4.32
Upside: -
Mar 20, 2018
Maintains: Outperform
Price Target: $70 → $84
Current: $17.40
Upside: +382.76%
Jul 11, 2017
Upgrades: Outperform
Price Target: n/a
Current: $1.93
Upside: -